Anthony M. Liang

Array ( [id] => 17749657 [patent_doc_number] => 20220227861 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => ANTI-MITOTIC COMPOSITION COMPRISING ANTIBODIES AGAINST ZIP6 AND/OR ZIP10 [patent_app_type] => utility [patent_app_number] => 17/618116 [patent_app_country] => US [patent_app_date] => 2020-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8787 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17618116 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18497465 [patent_doc_number] => 20230220105 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-13 [patent_title] => TUMOR ACTIVATED T CELL ENGAGERS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/616278 [patent_app_country] => US [patent_app_date] => 2020-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65373 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616278 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17945822 [patent_doc_number] => 20220332839 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => USE OF PRG4 TO TREAT CANCER [patent_app_type] => utility [patent_app_number] => 17/596066 [patent_app_country] => US [patent_app_date] => 2020-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24973 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17596066 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17748246 [patent_doc_number] => 20220226449 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => IMMUNOGENIC COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/614786 [patent_app_country] => US [patent_app_date] => 2020-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19296 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17614786 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20116047 [patent_doc_number] => 12365736 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-22 [patent_title] => ALK7 binding proteins and uses thereof [patent_app_type] => utility [patent_app_number] => 17/615508 [patent_app_country] => US [patent_app_date] => 2020-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41417 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 609 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17615508 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17704638 [patent_doc_number] => 20220204644 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => COMBINATION OF HER2 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/606523 [patent_app_country] => US [patent_app_date] => 2020-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8605 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17606523 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20527294 [patent_doc_number] => 12545718 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-10 [patent_title] => Anti-influenza B virus neuraminidase antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 17/605893 [patent_app_country] => US [patent_app_date] => 2020-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 75 [patent_no_of_words] => 94382 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 3491 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17605893 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17720489 [patent_doc_number] => 20220213209 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => MONOCLONAL ANTIBODY THAT BINDS SPECIFICALLY TO GITR [patent_app_type] => utility [patent_app_number] => 17/605933 [patent_app_country] => US [patent_app_date] => 2020-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30697 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17605933 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20492656 [patent_doc_number] => 12534519 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-27 [patent_title] => Molecules for therapy and diagnosis [patent_app_type] => utility [patent_app_number] => 17/603513 [patent_app_country] => US [patent_app_date] => 2020-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 18 [patent_no_of_words] => 76613 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 507 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17603513 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17704604 [patent_doc_number] => 20220204610 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => PROTEIN BINDERS FOR IRHOM2 [patent_app_type] => utility [patent_app_number] => 17/602183 [patent_app_country] => US [patent_app_date] => 2020-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13289 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17602183 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17578824 [patent_doc_number] => 20220135679 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => BISPECIFIC ANTIBODY SPECIFICALLY BINDING TO GPNMB AND CD3, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/431218 [patent_app_country] => US [patent_app_date] => 2020-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7418 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17431218 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19961649 [patent_doc_number] => 12331133 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-17 [patent_title] => Therapeutic antibodies for treating lung cancer [patent_app_type] => utility [patent_app_number] => 17/600862 [patent_app_country] => US [patent_app_date] => 2020-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 13418 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17600862 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17563210 [patent_doc_number] => 20220127359 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => ANTI-VBETA17/ANTI-CD123 BISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/437771 [patent_app_country] => US [patent_app_date] => 2020-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14762 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17437771 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17672708 [patent_doc_number] => 20220185875 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => BISPECIFIC ANTIBODY SPECIFICALLY BOUND TO VEGF AND ANG2 [patent_app_type] => utility [patent_app_number] => 17/439893 [patent_app_country] => US [patent_app_date] => 2020-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19925 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17439893 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17519331 [patent_doc_number] => 20220105179 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => GLYCOENGINEERING IMMUNOGLOBULIN E [patent_app_type] => utility [patent_app_number] => 17/430949 [patent_app_country] => US [patent_app_date] => 2020-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21669 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17430949 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17480728 [patent_doc_number] => 20220088232 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => ANTI-PD-L1 DIABODIES AND THE USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/425296 [patent_app_country] => US [patent_app_date] => 2020-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30713 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17425296 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17505217 [patent_doc_number] => 20220098319 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => CD73 ANTIBODY, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/422060 [patent_app_country] => US [patent_app_date] => 2020-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22263 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17422060 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17595347 [patent_doc_number] => 20220144920 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => ENGINEERING MONOCLONAL ANTIBODIES TO IMPROVE STABILITY AND PRODUCTION TITER [patent_app_type] => utility [patent_app_number] => 17/420231 [patent_app_country] => US [patent_app_date] => 2020-01-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13904 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17420231 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19855590 [patent_doc_number] => 12258413 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-25 [patent_title] => Bispecific antibody binding to TfR [patent_app_type] => utility [patent_app_number] => 17/418447 [patent_app_country] => US [patent_app_date] => 2019-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 29 [patent_no_of_words] => 50367 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 177 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17418447 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20158233 [patent_doc_number] => 12384845 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-12 [patent_title] => Activatable masked anti-CTLA4 binding proteins [patent_app_type] => utility [patent_app_number] => 17/417239 [patent_app_country] => US [patent_app_date] => 2019-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 84 [patent_figures_cnt] => 115 [patent_no_of_words] => 70414 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 253 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17417239 [rel_patent_id] =>[rel_patent_doc_number] =>)